H S Patel1, A R Silver, T Levine, G Williams, J M Northover. 1. Colorectal Cancer Genetics Group, Institute for Cell and Molecular Sciences, Barts and the London School of Medicine and Dentistry, London, UK.
Abstract
BACKGROUND: Immunosuppression is a known risk factor for anal human papillomavirus (HPV) disease, including anal squamous cell carcinoma. Additional risk factors for HPV-related disease have not been studied in the renal transplant population. The demographics of anal HPV and associated risk factors were investigated in this population. METHODS: Anal cytology and polymerase chain reaction were used to assess anal HPV disease in a cohort of transplant recipients at the Royal London Hospital. Risk factors associated with increased immunosuppression and HPV exposure were collated to determine any association with anal disease. RESULTS: Anal dysplasia was associated with anal oncogenic HPV infection (P < 0.001), duration of immunosuppression (P = 0.050), previous genital warts (P = 0.018) and receptive anal intercourse (P = 0.013). CONCLUSION: Anal dysplasia was related to immunosuppression and patient factors in this cohort.
BACKGROUND: Immunosuppression is a known risk factor for anal human papillomavirus (HPV) disease, including anal squamous cell carcinoma. Additional risk factors for HPV-related disease have not been studied in the renal transplant population. The demographics of anal HPV and associated risk factors were investigated in this population. METHODS: Anal cytology and polymerase chain reaction were used to assess anal HPV disease in a cohort of transplant recipients at the Royal London Hospital. Risk factors associated with increased immunosuppression and HPV exposure were collated to determine any association with anal disease. RESULTS:Anal dysplasia was associated with anal oncogenic HPV infection (P < 0.001), duration of immunosuppression (P = 0.050), previous genital warts (P = 0.018) and receptive anal intercourse (P = 0.013). CONCLUSION:Anal dysplasia was related to immunosuppression and patient factors in this cohort.
Authors: Anna-Barbara Moscicki; Teresa M Darragh; J Michael Berry-Lawhorn; Jennifer M Roberts; Michelle J Khan; Lori A Boardman; Elizabeth Chiao; Mark H Einstein; Stephen E Goldstone; Naomi Jay; Wendy M Likes; Elizabeth A Stier; Mark L Welton; Dorothy J Wiley; Joel M Palefsky Journal: J Low Genit Tract Dis Date: 2015-07 Impact factor: 1.925
Authors: Anna-Barbara Moscicki; Mark Schiffman; Ann Burchell; Ginesa Albero; Anna R Giuliano; Marc T Goodman; Susanne K Kjaer; Joel Palefsky Journal: Vaccine Date: 2012-11-20 Impact factor: 3.641
Authors: Robert Siegel; Ricardo Niklas Werner; Stephan Koswig; Matthew Gaskins; Claus Rödel; Felix Aigner Journal: Dtsch Arztebl Int Date: 2021-04-02 Impact factor: 8.251
Authors: A Albuquerque; H Pessegueiro Miranda; J Lopes; J Gandara; S Rodrigues; R Gaspar; R Morais; R Ramalho; E Rodrigues-Pinto; H Cardoso; H Barroca; C C Dias; F Carneiro; G Macedo Journal: Br J Cancer Date: 2017-10-31 Impact factor: 7.640
Authors: Xavier Martínez-Gómez; Adrian Curran; Magda Campins; Laia Alemany; José Ángel Rodrigo-Pendás; Natalia Borruel; Xavier Castellsagué; Cristina Díaz-de-Heredia; Fernando A Moraga-Llop; Marta Del Pino; Aureli Torné Journal: Euro Surveill Date: 2019-02